100% Free ACRP-CP Exam Dumps to Pass Exam Easily from Test4Cram
Free ACRP-CP Exam Questions ACRP-CP Actual Free Exam Questions
NEW QUESTION # 66
Who determines what criteria and procedures should be followed if a subject discontinues/withdraws their consent?
- A. Sponsor
- B. Subject
- C. CRO
- D. PI
Answer: A
Explanation:
The sponsor is responsible for defining the criteria and procedures for subject withdrawal or discontinuation of consent. This includes specifying how data already collected will be handled and whether any follow-up is required. The procedures must be clearly outlined in the study protocol and communicated to the research team.
This answer follows GCP guidelines, which state that the sponsor must ensure that procedures for subject withdrawal are clearly defined and documented.
"The sponsor is responsible for defining procedures to be followed if a subject discontinues participation or withdraws consent, including handling of data collected prior to withdrawal." Objectives:
* Ensure transparent procedures for participant withdrawal.
* Maintain data integrity while respecting participant autonomy.
NEW QUESTION # 67
In an investigator-initiated study, who is responsible for implementing appropriate corrective and preventive actions when significant non-compliance is discovered?
- A. CRC
- B. PI
- C. IRB/IEC
- D. CRA
Answer: B
Explanation:
In investigator-initiated studies, the PI holds primary responsibility for addressing non-compliance, including root cause analysis and implementation of CAPA plans. This ensures that any issues affecting the study's integrity are adequately addressed and prevented in the future.
The answer is verified based on ICH E6(R2) guidelines which emphasize the PI's responsibility for maintaining compliance at the study site.
"The PI must develop and implement corrective and preventive actions when non-compliance is identified during the study." Objectives:
* Maintain compliance in investigator-initiated studies.
* Address non-compliance through CAPA.
NEW QUESTION # 68
Per protocol, participants are scheduled to receive IP, which is calculated based on the participant's current weight. Unknown to the pharmacist, a participant recently lost 15 pounds and was overdosed as a result. What is the FIRST action the CRC must take to ensure the participant's safety?
- A. Report a protocol deviation to the IRB/IEC.
- B. Call the participant to return for an unscheduled visit.
- C. Notify the PI.
- D. Notify the sponsor.
Answer: C
Explanation:
The CRC's first responsibility is to immediately inform the Principal Investigator (PI), who is responsible for the participant's medical care. The PI will assess the situation, determine the potential risk, and initiate appropriate clinical actions to ensure the participant's safety. This may include medical evaluation or adjusting the dosing regimen.
According to GCP guidelines, any issue that may affect participant safety should be promptly communicated to the PI to ensure appropriate medical management.
"The investigator must be informed immediately of any events that could compromise participant safety, allowing for prompt clinical decision-making." Objectives:
* Ensure rapid response to dosing errors.
* Maintain participant safety as a priority.
NEW QUESTION # 69
The composition of an IDMC/DSMB should include which one of the following?
- A. A member from the IRB/IEC
- B. A sponsor representative who is knowledgeable about the study's unblinded information
- C. A clinical scientist who is knowledgeable in the appropriate discipline
- D. A lead PI for the study
Answer: C
Explanation:
An Independent Data Monitoring Committee (IDMC) or Data and Safety Monitoring Board (DSMB) should include clinical scientists who are knowledgeable in the relevant medical and scientific areas. Their role is to objectively assess the ongoing safety data and efficacy of the investigational product, ensuring that participants' safety is not compromised.
GCP guidelines emphasize the need for experienced clinical scientists on IDMC/DSMBs to ensure that safety data is interpreted accurately and professionally.
"IDMC/DSMB should comprise independent experts, including clinical scientists, who have the expertise to evaluate safety and efficacy data objectively." Objectives:
* Ensure impartial evaluation of safety data.
* Maintain scientific integrity in monitoring clinical trials.
NEW QUESTION # 70
Source data/documentation should be:
- A. Attributable, legible, correct, original, accurate, and clear.
- B. Attributable, legible, correct, original, accurate, and complete.
- C. Attributable, legible, contemporaneous, original, accurate, and complete.
- D. Attributable, legible, contemporaneous, original, accurate, and clear.
Answer: C
Explanation:
Source data/documentation in clinical trials must meet the ALCOA-C standard: Attributable, Legible, Contemporaneous, Original, Accurate, and Complete. This ensures that data is credible, traceable to the source, and maintains integrity throughout the study. These attributes are essential for maintaining high- quality, reliable, and verifiable clinical trial records.
GCP guidelines mandate that source documentation should adhere to the ALCOA-C principles to maintain data integrity and reliability.
"Source data must be attributable, legible, contemporaneous, original, accurate, and complete to meet quality and compliance standards." Objectives:
* Maintain data integrity and reliability.
* Adhere to best practices in clinical documentation.
NEW QUESTION # 71
In addition to members who collectively have the qualifications and experience to review and evaluate the science, medical aspects, and ethics of the proposed trial, it is recommended that the IRB/IEC should include:
- A. One member whose primary area of interest is in the same scientific area.
- B. One member of the site's QA group.
- C. One member who is independent of the institution/trial site.
- D. A total of five members.
Answer: C
Explanation:
The IRB/IEC should include at least one member who is not affiliated with the institution or trial site to ensure impartiality and objectivity in the review process. This helps maintain ethical oversight without internal biases influencing the decisions.
This answer is based on ICH E6(R2) GCP guidelines, which mandate the inclusion of non-affiliatedmembers to uphold the integrity of the ethical review process.
"The IRB/IEC should include at least one member who is not associated with the institution to provide an unbiased perspective." Objectives:
* Maintain impartiality in ethical review.
* Ensure diverse representation within the IRB/IEC.
NEW QUESTION # 72
What would a sponsor use to implement and maintain quality in a study?
- A. Standard operating procedures
- B. Clinical trial agreement
- C. Protocol signature pages
- D. Statistical analysis plan
Answer: A
Explanation:
Standard Operating Procedures (SOPs) are essential for implementing and maintaining quality in a clinical study. SOPs outline the standardized methods for conducting study-related tasks, ensuring consistency, compliance, and quality across all trial sites. They are critical for training personnel, guiding the conduct of study activities, and maintaining protocol adherence.
GCP guidelines state that sponsors must develop and maintain SOPs to ensure the quality and consistency of clinical trial processes.
"The sponsor should establish SOPs to maintain the quality of clinical trials, covering all aspects of trial conduct, data handling, and safety management." Objectives:
* Ensure consistent and high-quality trial conduct.
* Standardize procedures across trial sites.
NEW QUESTION # 73
In order to conduct open-label, parallel group clinical trials according to sound scientific principles, which of the following design elements should be included?
- A. Randomization
- B. Privacy controls
- C. Placebo-controlled
- D. Blinding
Answer: A
Explanation:
Randomization is a key element in open-label, parallel group clinical trials to reduce selection bias and ensure that participant allocation is not influenced by investigators. Despite the absence of blinding in open-label studies, randomization maintains the validity and reliability of the results by evenly distributing confounding factors between groups.
GCP guidelines recommend randomization as a core element in clinical trial design to ensure unbiased allocation of participants.
"Randomization in parallel group trials helps minimize selection bias and ensures the comparability of intervention groups." Objectives:
* Maintain scientific rigor through randomization.
* Minimize selection bias in clinical studies.
NEW QUESTION # 74
When assessing the monitoring needs for a study, sponsors should:
- A. Permit PIs to select a monitor for their site as long as they are independent of the PI.
- B. Use central monitoring instead of conducting physical monitoring visits at sites.
- C. Ensure monitoring visits are conducted at periodic intervals with a minimum of monthly monitoring visits.
- D. Ensure monitors have the scientific and/or clinical knowledge needed to monitor the trial adequately.
Answer: D
Explanation:
Sponsors must ensure that monitors are adequately qualified, possessing the necessary scientific and clinical knowledge to effectively oversee the trial. This ensures that monitors can accurately assess protocol compliance, data integrity, and participant safety. The quality of monitoring directly impacts the credibility of the trial outcomes.
GCP guidelines specify that monitors must be adequately trained and knowledgeable about the trial protocol, investigational product (IP), and clinical research standards.
"The sponsor must ensure that monitors have appropriate qualifications and training to conduct effective trial monitoring." Objectives:
* Maintain data integrity through skilled monitoring.
* Ensure patient safety and protocol compliance.
NEW QUESTION # 75
Which of the following should be considered when implementing a risk-based monitoring plan?
- A. 100% source document review is mandatory.
- B. Monitoring schedule must be pre-defined in the monitoring plan.
- C. On-site monitoring frequency may change depending on the quality of the data.
- D. Centralized monitoring must be incorporated in any trials.
Answer: C
Explanation:
Risk-based monitoring focuses on adapting the frequency and intensity of on-site visits based on data quality and site performance. If the data is consistently accurate and reliable, the monitoring frequency may be reduced. Conversely, if issues are identified, more frequent monitoring may be necessary.
GCP guidelines emphasize a flexible approach to monitoring, allowing adjustments based on the risk profile and quality of data collected.
"Risk-based monitoring involves adapting the frequency of on-site visits according to the quality of the data and the site's compliance level." Objectives:
* Implement a dynamic monitoring strategy.
* Enhance efficiency while maintaining data integrity.
NEW QUESTION # 76
A clinical trial is conducted to test the effect of an investigational drug on cholesterol levels. Statistical analysis will be performed to:
- A. Fail to reject the alternative hypothesis that the drug has an effect on cholesterol levels.
- B. Reject the null hypothesis that the drug has no effect on cholesterol levels.
- C. Reject the alternative hypothesis that the drug has no effect on cholesterol levels.
- D. Fail to reject the null hypothesis that the drug has an effect on cholesterol levels.
Answer: B
Explanation:
The purpose of statistical analysis in a clinical trial is to evaluate whether the data supports rejecting the null hypothesis, which typically states that there is no effect or difference. If the analysis finds a statistically significant result, the null hypothesis is rejected, indicating that the investigational drug has an effect on cholesterol levels.
The answer follows statistical principles in clinical trials, where the null hypothesis is rejected if evidence shows a significant difference or effect.
"In hypothesis testing, rejecting the null hypothesis indicates that the treatment effect is statistically significant." Objectives:
* Understand hypothesis testing in clinical research.
* Interpret statistical outcomes accurately.
NEW QUESTION # 77
In preparation for an upcoming site audit, whose responsibility is it to ensure study-related functions were conducted by qualified personnel?
- A. CRC
- B. Sponsor
- C. Investigator
- D. CRA
Answer: C
Explanation:
The Principal Investigator (PI) holds ultimate responsibility for ensuring that all study-related functions are conducted by qualified and trained personnel. The PI must verify that staff have the necessary qualifications and training to perform their assigned tasks as outlined in the protocol. This responsibility is crucial for maintaining compliance with GCP and ensuring data integrity.
According to GCP guidelines, the PI must ensure that all staff assisting with the trial are adequately trained and qualified for their roles.
"The investigator is responsible for ensuring that all persons assisting with the trial are qualified by education, training, and experience to perform their respective tasks." Objectives:
* Maintain compliance with GCP requirements.
* Ensure qualified personnel conduct study tasks.
NEW QUESTION # 78
An investigator in a multicenter trial reports multiple occurrences of an SAE to the sponsor. Who is responsible for reporting the SAEs to the remaining sites' IRB/IECs?
- A. Original reporting investigator
- B. Regulatory authority
- C. Investigator at each site
- D. Study sponsor
Answer: D
Explanation:
The study sponsor is responsible for disseminating information about SAEs to all participating sites. This ensures consistent and timely communication of safety concerns, allowing each site to take appropriate actions in line with local regulations and IRB/IEC requirements.
The answer aligns with ICH E6(R2) GCP guidelines which mandate the sponsor to communicatesafety information to all investigators and sites involved in a multicenter trial.
"The sponsor must inform all investigators of safety information that could affect the conduct of the trial or the safety of subjects." Objectives:
* Maintain consistent safety reporting across all trial sites.
* Ensure regulatory compliance in multicenter trials.
NEW QUESTION # 79
Which of the following elements of the Informed Consent are NOT required?
- A. Statement that study involves research
- B. Subject legal rights can be waived
- C. A description of potential benefits
- D. A description of any reasonably foreseeable risks or discomforts
Answer: B
Explanation:
Informed consent must not include any language that implies a waiver of the participant's legal rights or releases the investigator, sponsor, or institution from liability for negligence. Such language violates ethical standards and the principles of voluntary participation.
According to GCP guidelines and ethical principles, the informed consent document must not include any clause that waives a participant's legal rights.
"An informed consent form must not include language that waives the participant's legal rights or releases the sponsor or investigator from liability." Objectives:
* Protect participant rights in clinical trials.
* Ensure that consent is given voluntarily and ethically.
NEW QUESTION # 80
A deferred consent can take place in which of the following situations?
- A. Only when the PI approves such a consent process, regardless of the emergency situation described in the protocol.
- B. Only when the PI approves such a consent process immediately prior to patient enrollment, regardless of the situation being classed as emergency.
- C. In an emergency situation only, even when this process is not described in the protocol, but the sponsor approves the consent process.
- D. In an emergency situation only, when this process is described in the protocol and has received permission from the ethics committee.
Answer: D
Explanation:
Deferred consent is permissible in emergency situations where immediate intervention is necessary and obtaining prior consent is not feasible. However, this practice must be explicitly described in the protocol and approved by the ethics committee. This ensures that the rights of patients are protected even in urgent circumstances.
GCP guidelines emphasize that deferred consent is only allowed when pre-approved by the ethics committee as part of the protocol for emergency interventions.
"In emergencies, deferred consent is permitted only if outlined in the protocol and approved by the ethics committee, ensuring compliance with ethical standards." Objectives:
* Protect patient rights in emergency research.
* Ensure ethical approval for deferred consent.
NEW QUESTION # 81
SAEs must be reported immediately by the site to the:
- A. Regulatory agency.
- B. Sponsor.
- C. DSMB/IDMC.
- D. IRB/IEC.
Answer: B
Explanation:
Serious Adverse Events (SAEs) must be reported immediately to the sponsor. The sponsor then assesses the severity, causality, and potential impact on the study and decides whether further reporting to regulatory authorities and IRB/IEC is required. Immediate reporting ensures that appropriate actions are taken to safeguard participant safety.
GCP guidelines specify that the site must notify the sponsor immediately about any SAE to ensure timely safety assessment and reporting.
"Sites must report all serious adverse events immediately to the sponsor, who will then determine the appropriate regulatory and ethical reporting requirements." Objectives:
* Ensure rapid reporting of serious adverse events.
* Maintain safety monitoring during the trial.
NEW QUESTION # 82
A study has been closed for two years after the last approval of a marketing application of an IP. No additional applications are pending and there are no further developments planned for the IP. Which of the following statements is the BEST course of action regarding the destruction of the essential documents?
- A. The site should retain the essential documents longer to meet the regulatory requirements.
- B. The site should contact the sponsor and receive verbal notification they are no longer needed andthe essential documents may be destroyed.
- C. The site may proceed with the destruction of the essential documents.
- D. The site should contact the sponsor and receive written notification prior to destruction that the essential documents are no longer needed.
Answer: D
Explanation:
Before destroying any essential documents, the site must obtain written confirmation from the sponsor that these documents are no longer needed. This ensures compliance with regulatory requirements, as some countries may require document retention for longer periods, even after study closure and marketing approval.
GCP guidelines state that the sponsor must confirm in writing that essential documents can be destroyed after ensuring compliance with local regulations.
"Before destroying essential documents, written confirmation from the sponsor is required to ensure compliance with regulatory retention policies." Objectives:
* Maintain compliance with document retention regulations.
* Prevent premature destruction of essential trial records.
NEW QUESTION # 83
A trial subject was involved in a traffic accident. The emergency room (ER) doctor notifies the investigator that he wants to give the subject a blood transfusion. Blood transfusion is one of the prohibited treatments in the trial. How should the investigator respond?
- A. Ask the ER doctor not to transfuse blood and consider another treatment compliant with the protocol.
- B. Advise the ER doctor to transfuse the blood, and the PI should report this incident to the sponsor.
- C. Advise the ER doctor to transfuse blood, and the PI should withdraw the subject from the trial.
- D. Report this incident immediately to the sponsor and leave the treatment decision to them.
Answer: B
Explanation:
The investigator must prioritize the subject's immediate health and safety. In a medical emergency, the appropriate response is to advise the ER doctor to proceed with the necessary medical intervention (blood transfusion). Afterward, the PI must promptly report the incident to the sponsor as a protocol deviation.
GCP guidelines emphasize that patient safety takes precedence over protocol requirements in emergency situations.
"In situations where immediate medical intervention is necessary to prevent harm, the investigator should ensure that the appropriate care is given and subsequently report the event as a deviation." Objectives:
* Prioritize patient safety in emergencies.
* Report protocol deviations promptly.
NEW QUESTION # 84
Who is responsible for submitting a protocol amendment to the IRB/IEC?
- A. CRC
- B. Sponsor
- C. Investigator
- D. CRA
Answer: C
Explanation:
The investigator holds the responsibility for submitting any protocol amendments to the IRB/IEC for review and approval. This step ensures that all changes are ethically evaluated before being implemented, maintaining compliance with regulatory requirements.
According to GCP guidelines, the investigator must submit protocol changes to the IRB/IEC to secure approval before making any modifications to the study.
"The investigator must inform the IRB/IEC of any proposed protocol changes and secure approval prior to implementation." Objectives:
* Maintain ethical oversight in study modifications.
* Adhere to regulatory submission requirements.
NEW QUESTION # 85
A clinical trial where participants will be randomized to receive a sequence of two medications has which design configuration?
- A. Factorial
- B. Parallel Group
- C. Group sequential
- D. Crossover
Answer: D
Explanation:
A crossover study design involves participants receiving multiple interventions sequentially, with a washout period in between to minimize carryover effects. This design allows each participant to serve as their own control, increasing statistical power while reducing variability. It is commonly used when comparing two treatments or interventions.
GCP guidelines classify a crossover design as one where subjects receive multiple treatments in a specified sequence.
"In crossover trials, participants receive each intervention in a specific order, allowing for within-subject comparison." Objectives:
* Understand the structure of crossover studies.
* Improve statistical efficiency through self-control comparisons.
NEW QUESTION # 86
A potential subject is interested in a new clinical trial and would like to learn more about the risks and benefits of participation. Where can they find this information?
- A. IB
- B. Protocol
- C. ICF
- D. Package insert
Answer: C
Explanation:
The Informed Consent Form (ICF) contains comprehensive information about the potential risks and benefits of participation in a clinical trial. It is a legally required document that ensures that subjects make an informed decision before enrollment.
The answer is consistent with GCP guidelines which mandate that the ICF clearly outlines the risks and benefits of participation to protect participant rights.
"The ICF should include a clear explanation of potential risks and benefits to ensure informed decision- making by the participant." Objectives:
* Ensure informed decision-making by potential subjects.
* Provide transparent risk-benefit information.
NEW QUESTION # 87
A site is starting up a Phase III trial. They have received IRB/IEC approval and have scheduled the SIV. The site cannot begin enrolling subjects until:
- A. The site receives approval from the medical monitor to begin enrolling.
- B. The CRA has performed source document review and verification at the site.
- C. A signed clinical trial agreement between the site and sponsor is in place.
- D. The DSMB meets and the first DSMB meeting report has been issued.
Answer: C
Explanation:
Before a clinical trial site can begin enrolling participants, there must be a signed clinical trial agreement (CTA) between the site and the sponsor. This agreement outlines the responsibilities, financial arrangements, and expectations between both parties, ensuring that the trial is conducted in compliance with regulatory and ethical standards.
GCP guidelines require that a formal agreement be in place before trial initiation to protect the rights and obligations of both the sponsor and the site.
"Before subject enrollment can commence, the sponsor and site must finalize a clinical trial agreement, establishing legal and ethical commitments." Objectives:
* Ensure proper contractual arrangements before trial initiation.
* Protect legal rights and obligations of involved parties.
NEW QUESTION # 88
Which of the following documents is maintained by a PI to ensure compliance with sponsor requirements?
- A. Training records of site personnel on study protocol, and their study-related duties and functions.
- B. Regulatory submission of protocol and accompanying documents to relevant regulatory authority.
- C. A monitoring report that identifies deviation from the approved protocol.
- D. A monitoring plan that is tailored to the specific human subject protection and data integrity risks of the trial.
Answer: A
NEW QUESTION # 89
Confidentiality and privacy rules for protection of human subjects at research sites are determined by the:
- A. Applicable site SOPs
- B. Sponsor
- C. Applicable regulatory authorities
- D. PI
Answer: C
Explanation:
The confidentiality and privacy rules protecting human subjects in clinical research are established by applicable regulatory authorities, such as the FDA or EMA, and must be followed by all research sites. These regulations ensure that participants' personal data are handled securely and ethically.
GCP guidelines mandate compliance with local, national, and international regulations regarding data confidentiality and privacy.
"Confidentiality and privacy protections are determined by applicable regulatory authorities and must be adhered to by all study sites." Objectives:
* Protect participant privacy.
* Ensure compliance with data protection regulations.
NEW QUESTION # 90
The coding system for a double-blind clinical trial is accessible by the:
- A. Sponsor
- B. Regulatory authority
- C. IRB/IEC
- D. PI
Answer: A
Explanation:
The sponsor is typically responsible for maintaining the code that links the treatment assignment to participants in a double-blind clinical trial. The code is securely maintained and is only accessible in cases where unblinding is necessary for safety reasons. This process helps to preserve the integrity of the study while allowing for emergency unblinding if needed.
GCP guidelines state that the sponsor should maintain the blind unless unblinding is necessary due to safety concerns or regulatory requirements.
"The sponsor maintains the randomization code and ensures that unblinding occurs only when necessary, to protect the study's integrity." Objectives:
* Maintain the integrity of double-blind trials.
* Allow controlled access to randomization codes.
NEW QUESTION # 91
......
Latest 100% Passing Guarantee - Brilliant ACRP-CP Exam Questions PDF: https://www.test4cram.com/ACRP-CP_real-exam-dumps.html
Verified ACRP-CP dumps and 127 unique questions: https://drive.google.com/open?id=1wWQGzzkKlpRMbF0zTATaE4YsQqF2on9l